Scribe Therapeutics Inc. (SCTX)
| Market Cap | 536.50M |
| Revenue (ttm) | 36.28M +86.7% |
| Net Income | -35.73M |
| EPS | -14.64 |
| Shares Out | 18.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 201,597 |
| Open | 28.78 |
| Previous Close | 28.84 |
| Day's Range | 27.99 - 34.64 |
| 52-Week Range | 17.31 - 39.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 56.00 (+96.91%) |
| Earnings Date | Sep 11, 2026 |
About SCTX
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SCTX stock is "Strong Buy." The 12-month stock price target is $56.0, which is an increase of 96.91% from the latest price.
News
Leerink starts Scribe Therapeutics at Outperform on X-editor platform
As previously reported, Leerink initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target The firm views Scribe as a “pioneer in the development of safe…
Scribe Therapeutics initiated with an Outperform at Leerink
Leerink analyst David Risinger initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target
Scribe Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Scribe Therapeutics (SCTX) with a Buy rating and $50 price target The company has developed two proprietary CRISPR platforms for “best-in-class” epigenetic and genetic...
Scribe Therapeutics initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Scribe Therapeutics (SCTX) with an Overweight rating and $60 price target The firm views the company’s ELXR as a “differentiated” epigenetic silencing platform, poten...
Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Goldman Sachs initiated coverage of Scribe Therapeutics (SCTX) with an Early-Stage Biotech rating. It believes STX-1150 “could have best of both world attributes” with siRNA’s reversibility silencing ...
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront…
Scribe Therapeutics opens at $25, IPO priced at $15 per share
Scribe Therapeutics (SCTX), which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into “purpose-built in vivo genetic me...
Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share
11:21 EDT Scribe Therapeutics (SCTX) indicated to open at $25, IPO priced at $15 per share
Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share
Scribe Therapeutics (SCTX) priced 8.58M shares at $15.00. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Scribe Therapeutics is a clinical-st...
Scribe Therapeutics 8.58M share IPO priced at $15.00
The deal guidance is towards the high-end of the $13.,00-$15.00 range. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Published first on…
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Scribe Therapeutics IPO Registration Document (S-1)
Scribe Therapeutics has filed to go public with an IPO on the NASDAQ
Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO
Scribe Therapeutics, a Phase 1 biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.